Back to Search
Start Over
S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX
- Source :
- HemaSphere, Vol 7, p e72578ff (2023)
- Publication Year :
- 2023
- Publisher :
- Wiley, 2023.
- Subjects :
- Diseases of the blood and blood-forming organs
RC633-647.5
Subjects
Details
- Language :
- English
- ISSN :
- 25729241
- Volume :
- 7
- Database :
- Directory of Open Access Journals
- Journal :
- HemaSphere
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.8edee251cd8b493bbb10d982f407011f
- Document Type :
- article
- Full Text :
- https://doi.org/10.1097/01.HS9.0000967752.72578.ff